Why the study?
What is the prevalence of metabolic syndrome and its association with adipokine levels and disease severity in patients with SLE and SSc?
What is the prevalence of metabolic syndrome and its association with adipokine levels and disease severity in patients with SLE and SSc?
Metabolic syndrome is more prevalent in SLE than SSc and is associated with altered adipokine profiles and higher disease severity.
May warrant metabolic screening in SLE; leaves open whether adipokine changes drive severity.
Prevalence of MetS is higher in SLE patients. In SLE patients, MetS showed an association with adipokine levels and inflammation/activity disease scores. In SSc patients, MetS was associated with severity of disease. Key Points • Prevalence of metabolic syndrome is higher in SLE patients than SSc patients. • Resistin is higher in SLE patients with metabolic syndrome. • Adineponectin is lower in SLE patients with metabolic syndrome. • Disease severity scale is higher in SSc patients with metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Gigante et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: